LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc.

VANCOUVER, BC / ACCESS Newswire / April 20, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790) (WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that it has entered into a Technology Development Collaboration Agreement (the "Agreement") with Resilience BioSciences Inc. ("RBI"), a Vancouver-based drug discovery and development company, to support and expand LIR's ongoing preclinical research activities.

Under the Agreement, LIR intends to collaborate with RBI's scientific team within their newly established, state-of-the-art facilities at the adMare BioInnovations site, located within the Pharmaceutical Sciences Building at the University of British Columbia (UBC). As part of this collaboration, LIR will conduct certain early-stage experimental work, including ex vivo porcine skin and formulation studies within RBI's facilities.

RBI's facility is situated within a leading academic research environment, providing proximity to academic expertise, modern laboratory infrastructure, and established research support services. LIR believes this setting is well aligned with the Company's emphasis on rigorous, human-relevant preclinical validation.

"This Agreement is about execution and efficiency," said Edward Mills, CEO of LIR Life Sciences. "As our preclinical programs expand, working within a high-quality laboratory environment and alongside experienced scientific teams in a leading academic environment allows us to move studies forward in a focused and cost-effective manner."

"We are pleased to support this collaboration with LIR Life Sciences within a rigorous translational research environment," said Dr. Anthony Phillips, CEO of Resilience BioSciences. "Our approach integrates preclinical science with clinical insight to accelerate the development of novel therapies."

Matthew Roberts, Chief Operations Advisor at Resilience BioSciences, added: "This agreement reflects our focus on supporting innovative therapeutic development through integrated preclinical capabilities, while advancing our own pipeline of non-opioid therapeutics targeting opioid withdrawal and associated pain. We look forward to undertaking a structured evaluation of LIR's delivery technology as it progresses, with the potential for future application within our own development programs."